IQVIA (NYSE: IQV) Expands Early-Stage Drug Discovery Capabilities with Acquisition of Charles River Discovery Assets IQVIA Holdings Inc. (NYSE: IQV) announced an agreement to acquire select discovery services assets from Charles River Laboratories, strengthening its early-stage R&D capabilities. The assets include five sites offering in vitro drug discovery, AI-driven small molecule platforms, and advanced non-animal research methods backed by over 20 years of scientific data. These capabilities will enhance IQVIA’s integrated platform across drug discovery, from target identification to early safety assessment, covering key therapeutic areas like oncology, neurology, and immunology. The move positions IQVIA to support clients earlier in the drug development lifecycle. The transaction is expected to close in Q2 2026. (Link)
GSK (NYSE: GSK) Agrees to Acquire 35Pharma for $950 Million to Bolster Cardiopulmonary Pipeline GSK announced an agreement to acquire 35Pharma Inc., a Canada-based clinical-stage biopharma company focused on novel protein-based therapeutics. The deal gives GSK full ownership of 35Pharma and its lead asset HS235, a potential best-in-class activin receptor signaling inhibitor targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The acquisition strengthens GSK’s Respiratory, Immunology and Inflammation portfolio, addressing unmet needs in a high-burden disease with a growing market projected to reach $18 billion by 2032. GSK will pay $950 million in cash for 100% equity, subject to regulatory approvals, with closing expected thereafter. (Link)
Exa Capital Expands Healthcare Software Portfolio with Acquisition of StaffReady, a Leader in Clinical Workforce Management SaaS Exa Capital, a long-term investor specializing in enterprise software, has acquired StaffReady, a SaaS platform for clinical workforce management in healthcare. Founded in 1995, StaffReady provides cloud-native tools for staff scheduling, compliance, and inspection readiness across hospital departments and life sciences organizations. The deal strengthens Exa Capital’s healthcare technology portfolio and marks its entry into clinical workforce optimization, a sector critical to operational efficiency and patient safety. StaffReady will continue to operate independently under Exa’s decentralized model, with its leadership team remaining in place to drive innovation and sustainable growth backed by Exa’s strategic support. (Link)
Numantec Expands Infusion Therapy Portfolio with Acquisition of DualCap® Product Line from Merit Medical financed by Banco BPM and Muzinich & Co Numantec, a global infusion therapy device manufacturer, has acquired the DualCap® product line from Merit Medical Systems through its U.S. subsidiary, Health Line International Corp. The DualCap® is an established antimicrobial cap used in vascular access and infusion therapy, enhancing infection prevention and clinical efficiency. The acquisition strengthens Numantec’s vascular access portfolio and creates growth opportunities across Europe and the U.S., where DualCap® already has a strong customer base. Health Line, which has manufactured DualCap® since before 2017, will ensure continuity of supply. The transaction was financed by Banco BPM and Muzinich & Co. (Link)
Healthcare Triangle (Nasd: HCTI) Announces $3.96 Million Registered Direct Offering Priced at-the-Market to Support Growth Initiatives Healthcare Triangle, Inc. (Nasdaq: HCTI), a digital transformation leader for healthcare and life sciences, announced it has entered into definitive agreements to sell 681,553 shares of common stock (or prefunded warrants) at $5.81 per share in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds are expected to total approximately $3.96 million before fees and expenses. The offering, conducted under the company’s effective Form S-3 shelf registration, is expected to close around February 27, 2026, subject to customary conditions. (Link)
The HWP Group Acquires Global Market Access Solutions to Strengthen Market Access and Health Economics Expertise Backed by NMS Capital The HWP Group, a leading medical communications and strategic consulting firm for the life sciences sector, has acquired Global Market Access Solutions (GMAS), a global consultancy specializing in market access and health economics. The acquisition expands HWP’s capabilities in HEOR, pricing and payer insights, evidence synthesis, and lifecycle value strategy, enhancing support across the entire product lifecycle—from early development to sustained patient access. CEO Jani Hegarty said the deal reinforces HWP’s mission to bridge science and real-world access. Backed by NMS Capital, the move positions HWP as a fully integrated partner for pharmaceutical and biotechnology innovators. (Link)
QC Capital Invests in My Pediatric Doctor to Expand Nationwide 24/7 Urgent Pediatric Telehealth Platform QC Capital Group, a Charlotte-based alternative investment firm, announced a strategic investment in My Pediatric Doctor, a nationwide 24/7 pediatric telehealth platform offering on-demand access to board-certified providers. Led by CEO Eric Doherty, the company aims to modernize pediatric care by reducing emergency room visits and improving accessibility for families across all 50 states, Guam, and Puerto Rico. The platform integrates with healthcare systems to relieve pressure on hospitals while maintaining high clinical standards. QC Capital CEO Chris Salerno called the partnership a key step in delivering trusted, affordable pediatric care nationwide. (Link)
HCAP Partners Leads Follow-On Acquisition to Expand Integrated Diagnostic Services Platform with Core Analytics Lab & Radiology other partners include California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine San Diego-based private equity and impact investor HCAP Partners has completed a follow-on acquisition for its Integrated Diagnostic Services (IDS) platform with the addition of Santa Fe Springs-based Core Analytics Lab & Radiology. The deal expands IDS’s footprint into Northern California and adds mobile laboratory diagnostics to its service offerings. Financing was provided by HCAP Partners, California Bank & Trust, along with co-investment from St. Cloud Capital and Southfield Mezzanine. Post-acquisition, IDS will serve over 440 facilities, offering bundled radiology and lab services to skilled nursing, long-term care, and home health providers across California. (Link)
Gemspring Capital Expands Spinal Device Platform as Portfolio Company Zavation Medical Acquires ChoiceSpine Zavation Medical Products, a Gemspring Capital portfolio company and manufacturer of spinal implants and biologics, has acquired ChoiceSpine Holdings, a Knoxville-based spinal implant designer. The transaction broadens Zavation’s product portfolio and national reach, leveraging its vertically integrated manufacturing to accelerate innovation. ChoiceSpine will keep its brand and operations during integration. Concurrently, Zavation appointed Derek Kuyper as CEO of the combined entity. Gemspring Capital said the acquisition strengthens Zavation’s market position and supports its strategy to build a scaled, innovation-driven spinal platform. (Link)
Fulcrum Equity Partners Leads $10M Growth Round in MedScout to Advance AI-Driven MedTech Sales Execution with participation from Live Oak Venture Partners and Stage 2 Capital Austin-based MedScout has raised $10 million in a growth funding round led by Fulcrum Equity Partners, with participation from Live Oak Venture Partners and Stage 2 Capital. The funding more than doubles MedScout’s valuation since its Series A in July 2024. The company also launched “Strategies,” a suite of AI agents designed to help MedTech commercial teams translate strategy into field-level execution. MedScout plans to use the capital to expand its AI capabilities amid surging enterprise demand. The company reported tripled enterprise revenue and rapid adoption growth as investors back its data-driven approach to commercial alignment in MedTech sales. (Link)
Chapters Health Expands West Coast Footprint with Housecall Providers Deal, Strengthening Nonprofit Hospice Network and Growth Potential Chapters Health System, the nation’s largest nonprofit hospice network, has signed a definitive agreement to acquire Housecall Providers from CareOregon, pending approval by the Oregon Health Authority. The move expands its Pacific Northwest presence and adds to its 2025 West Division growth, which includes affiliates in California, Nevada, and Oregon. The integration aligns two nonprofit leaders in community-based chronic and homecare, reinforcing Chapters’ national scale, operational synergies, and value-based care capabilities—key drivers for investors tracking nonprofit healthcare consolidation and sustainable care delivery models. (Link)
Dovida Enters U.S. Market with Acquisition of A Place At Home, Expanding Global Home Care Footprint to Seven Countries Global home care provider Dovida has entered the U.S. market through the acquisition of A Place At Home, a nationwide home care franchise network. The move marks Dovida’s seventh international market and first presence in North America, extending its person-centered care model across the United States. A Place At Home’s leadership will remain in place to ensure continuity for franchise owners and caregivers. The deal aligns with Dovida’s strategy to expand amid increasing demand for high-quality in-home care for older adults, reinforcing its mission to deliver personal, dignified, and relationship-based care on a global scale. (Link)
Ally Bridge Group Backs Creation of Precision IO Group as Quantum Surgical Acquires NeuWave Medical to Advance Robotic Cancer Care Quantum Surgical has acquired NeuWave Medical, Inc., combining expertise in robotic and microwave ablation technologies under a new parent entity, Precision IO Group Inc., led by medtech veteran Kurt Azarbarzin. Supported by investment from Ally Bridge Group, the group aims to expand access to minimally invasive, AI-driven, and remote cancer treatments worldwide. Both companies will continue operating independently, ensuring ongoing product availability. The Epione robotic platform and NeuWave’s microwave system will together drive broader adoption of next-generation interventional oncology procedures across global healthcare markets. (Link)
HIAAH Expands Mental Health Footprint with Strategic Acquisition of Broward Center for Counseling to Strengthen Market Presence in Broward County HIAAH, a U.S.-based integrated health care and mental health services provider, has acquired the Broward Center for Counseling as part of its expansion strategy in Broward County. The move reinforces HIAAH’s mission to broaden access to high-quality, compassionate mental health care while improving operational efficiency and client experience. The newly branded Broward Center for Counseling by HIAAH will continue providing individualized therapy for anxiety, depression, trauma, and relationship issues, now supported by enhanced infrastructure and a holistic, multidisciplinary care model. The acquisition aligns with HIAAH’s growth objectives and positions it for stronger long-term value creation in the behavioral health sector. (Link)
UConn Health Finalizes Waterbury Hospital Acquisition from Prospect Medical Holdings UConn Health is set to complete its acquisition of Waterbury Hospital from bankrupt for-profit Prospect Medical Holdings at midnight on Saturday, marking a major expansion of its health network. The facility will operate under a new entity, UConn Health Community Network, beginning Sunday at 12:01 a.m. Immediate changes include new signage, updated processes, and a ribbon-cutting ceremony on March 4. UConn Health plans to assess Waterbury’s healthcare needs, modernize information and safety systems, and introduce new specialists and services from its flagship John Dempsey Hospital in Farmington to strengthen local medical care and patient outcomes. (Link)
Bradford Health Expands into Midwest with Acquisition of Parkdale Center, Strengthening National Footprint in Specialized Professional Addiction Care Bradford Health Services, a nationally recognized addiction treatment provider, has acquired Parkdale Center, a leading Indiana-based facility specializing in confidential addiction recovery programs for healthcare providers, attorneys, executives, and other licensed professionals. The deal extends Bradford’s geographic reach into the Midwest and enhances its portfolio of evidence-based treatment offerings. Parkdale’s expertise in professional recovery, career reentry, and collaboration with licensing boards complements Bradford’s mission of clinical excellence and sustainable outcomes. Both organizations will maintain their brands while integrating operations to deliver expanded, high-quality care for professionals nationwide. Terms of the transaction were not disclosed. (Link)
Zemantics Ventures Strengthens Healthcare Portfolio with Acquisition of Consilium360 and MedWell360 Zemantics Ventures, a strategic investment and operating platform, has acquired Consilium360 and MedWell360 to expand its presence in healthcare services and workforce solutions. The move enhances Zemantics’ capabilities in enterprise HR optimization, patient access, and technology-enabled operational performance. Consilium360 provides data-driven workforce and HR strategy solutions for healthcare systems, while MedWell360 specializes in scheduling and access center services. The acquisitions support Zemantics’ strategy of scaling founder-led, service-driven businesses through strategic capital, shared infrastructure, and technology. John Brown, Founder and Healthcare HR Executive, will continue in a leadership role to ensure continuity and growth. (Link)
Epiphany Dermatology Expands Kansas Presence Through Partnership with Resolute Dermatology Epiphany Dermatology, a leading national dermatology network, has expanded its presence in Kansas by partnering with Resolute Dermatology, LLC, founded in 2020 by Dr. Daniel Christiansen. Based in Leawood and Shawnee, KS, Resolute Dermatology is recognized for high-quality patient care in the greater Kansas City area. The partnership brings Dr. Christiansen and his team—Drs. Julie Green, Elizabeth Spenceri, and PAs Judy Ky and Kylie Witham—into Epiphany’s growing network. Through this collaboration, Resolute gains operational and clinical support while sharing expertise across Epiphany’s 123 locations in 18 states, strengthening access to exceptional dermatologic care in the region. (Link)
Venture and Other News:
NewSpring Healthcare Leads $140 Million Investment in Honest Health to Accelerate Value-Based Care Expansion included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners Honest Health, a physician-led value-based care enablement firm, raised $140 million in a funding round led by NewSpring Healthcare, the healthcare-focused arm of NewSpring Capital. The round included participation from K2 HealthVentures and existing investors Rubicon Founders, Oak HC/FT, WCAS, and Durable Capital Partners. Proceeds will support national expansion and partnerships with health systems and payers. NewSpring will leverage its sector expertise to guide Honest Health’s growth in risk-based care models. (Link)
NantWorks Leads $240 Million Investment in SHINE Technologies; Dr. Patrick Soon-Shiong Joins Board to Advance Fusion and Cancer Therapies SHINE Technologies, a leader in fusion-based technology, has raised $240 million in new equity funding led by NantWorks, founded by Dr. Patrick Soon-Shiong, who also joins SHINE’s Board of Directors. Other investors include Fidelity, Sumitomo, Pelican Energy, Deerfield, and Oaktree. The funding supports SHINE’s commercial fusion initiatives in neutron testing, medical isotope production, and nuclear waste recycling, while accelerating Lu-177 radioisotope supply for precision cancer therapies. The strategic partnership gives NantWorks priority access to Lu-177, aligning SHINE’s fusion expertise with Soon-Shiong’s mission to transform oncology. With this round, SHINE’s total funding surpasses $1 billion. (Link)
BrainCheck Secures Additional $13 Million Series A to Scale AI-Enabled Cognitive Care Platform and Embedded Assessment Workflows Across Value-Based Health Systems BrainCheck, a digital platform for cognitive assessment and care, has raised an additional $13 million in Series A financing led by Next Coast Ventures, with S3 Ventures and UPMC Enterprises participating. The capital will expand its enterprise cognitive care infrastructure, including deeper EHR integration, longitudinal monitoring, AI-assisted population health analytics, and deployment across primary care and specialty settings. BrainCheck is partnering with collaborative care organizations to operationalize scalable cognitive care pathways in time-constrained, value-based environments. Used by 500+ providers, its FDA Class II BrainCheck Assess™ has powered over 640,000 assessments and 14,000 care plans to date. (Link)
YOU(th) Health Tech Raises $4.5M to Expand Smartphone-Based Preventive Health Screening Globally round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Digital health startup YOU(th) has raised $4.5 million in a funding round led by Callisto Health, with support from caesar., adesso Ventures, Antler, Moonstone, and 1024 Ventures. Angel investors include Jean-Charles Samuelian (Alan, Mistral AI) and Patrick Andrae (HomeToGo). The company aims to democratize preventive healthcare by turning everyday smartphone data—such as facial videos, voice, typing patterns, and step counts—into quick health assessments detecting over 50 biomarkers across 10 organ systems. The funds will support product development and expansion of engineering, data science, and medical research teams to make preventive care accessible worldwide. (Link)
General Catalyst Leads $6.5M Seed in Baba to Build Continuous AI‑Enabled Patient Advocacy for Aging Americans General Catalyst has led a more than $6.5 million seed round in Baba, a patient advocacy startup founded by Connor Sweeney to help seniors and families navigate complex healthcare logistics. Inspired by his grandparents’ experience after his grandmother’s stroke, Sweeney built Baba to pair older adults with dedicated human advocates, augmented by AI tools for daily check-ins, medication management, and insurance and benefits navigation. With advocacy reimbursed by Medicare for over 70 million beneficiaries, Baba aims to scale continuous, preventive support through partnerships with home health, nursing homes, and post-acute care providers. (Link)
Coral Care Raises $13M Series A Led by Haymaker Ventures, Joined by FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures to Expand In-Home Pediatric Therapy Nationwide Coral Care, a platform providing in-home pediatric speech, occupational, and physical therapy, has raised a $13 million Series A round led by Haymaker Ventures, with participation from FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures, and Charge Ventures. The funding will fuel national expansion in Dallas, Houston, Chicago, Philadelphia, and Pittsburgh, bringing operations to five states. Founded in 2023 by Jen Wirt, Coral Care supports over 400 licensed clinicians through its technology platform that streamlines administrative tasks and enables accessible, insurance-covered, in-home therapy for children across the U.S. (Link)
AI Healthtech Startup Lexi Raises $1.4M Pre-Seed Round Led by Informed Ventures, Backed by HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures Lexi, an AI-native communication platform for healthcare, has raised an oversubscribed $1.4 million pre-seed round led by Informed Ventures, with participation from HBS Alumni Angels, Stanford Angels, Alumni Ventures, and Van Wickle Ventures. Founded by Linh Pham and Siddharth UR, Lexi tackles language barriers affecting 30 million U.S. patients by providing secure, instant AI interpretation within clinical workflows. A successful pilot with Lowell Community Health Center delivered over 60,000 minutes of interpretation, reduced costs by 60%, and improved privacy and efficiency. Lexi plans to expand deployments across health centers while broadening language coverage and patient partnerships. (Link)
Ro: Serena Williams promotes GLP-1 telehealth. (Link)
Novartis: Encourages prostate cancer blood test screening. (Link)
Boehringer Ingelheim: Raises awareness for kidney disease screening. (Link)
TrumpRx launches with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to offer discounted drugs for U.S. cash‑paying patients under Most favoured Nation policy The TrumpRx direct‑to‑consumer platform introduces over 40 discounted prescription drugs to help uninsured or cash‑paying U.S. patients access more affordable treatments. The initiative, backed by the first five pharmaceutical companies signing pricing deals under the Most Favoured Nation policy, includes major blockbusters such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both offered at significantly reduced prices. Additional products include insulin, fertility therapies, and inhalers from Pfizer and others. Sixteen global drugmakers are expected to join the platform, which aims to align U.S. medication prices with international standards while reshaping the domestic pricing landscape and consumer access dynamics. (Link)
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal Takeda Pharmaceutical enters multi-year AI drug discovery collaboration with Iambic Therapeutics worth more than $1.7 billion to accelerate small-molecule development in oncology, inflammation, and gastrointestinal diseases. The partnership underscores Takeda’s push to fully integrate AI into its R&D engine, following prior deals like its Nabla Bio collaboration, as big pharma bets on AI to speed discovery, reduce costs, and target complex diseases more precisely. Iambic, a San Diego-based biotech with a growing pipeline of AI-discovered candidates, gains validation and funding to expand its platform amid surging interest in AI-driven drug design. (Link)
Once Upon a Farm (NYSE: OFRM) raises $198M in NYSE IPO backed by Goldman Sachs and J.P. Morgan to expand organic children’s food business co-founded by Jennifer Garner The company’s public debut marks a major milestone for the organic children’s food brand, offering 11 million shares at $18 each. Founded by Cassandra Curtis and Ari Raz in 2015 and later joined by Jennifer Garner and John Foraker, Once Upon a Farm produces cold-pressed pouches, frozen meals, and oat bars made from responsibly sourced fruits and vegetables. The IPO strengthens its ability to meet rising consumer demand for clean, nutritious food products while amplifying its retail presence. Despite global supply challenges, the company aims to grow amid increasing momentum in the health-conscious food and beverage market. (Link)
TenetHealthcare (NYSE: THC) receives $1.9B from CommonSpirit to regain full ownership of Conifer Health Solutions Under the agreement, CommonSpirit will pay Tenet Healthcare $1.9 billion in instalments over three years to sell its 23.8% equity stake in Conifer Health Solutions, Tenet’s revenue cycle management subsidiary. The transaction, retroactive to January 1, 2026, also includes a $540 million payment from Conifer to eliminate CommonSpirit’s capital account and finalize the stake redemption. Conifer will continue providing services to CommonSpirit through the end of 2026 while onboarding new clients. Tenet expects the move to strengthen its financial outlook, citing operational efficiency, revenue growth, and strategic alignment as key drivers for sustaining profitability and future expansion. (Link)
PrimeGen US to merge with DT Cloud Star Acquisition Corporation (NASD: DTSQ) in a $1.5B business combination to accelerate stem cell and exosome therapy development The merger will position PrimeGen US for public market access and expanded funding to advance its regenerative medicine portfolio. The company’s lead program centers on its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform, being developed as a treatment for acute alcoholic hepatitis and other liver-related conditions. The deal, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will support clinical progression, regulatory submissions, and potential commercialization. PrimeGen’s leadership emphasized that the transaction marks a major step toward scaling its two-decade foundation in stem cell innovation into transformative therapies for critical diseases. (Link)
Eikon Therapeutics (NASD: EIKN) raises $381M in upsized Nasdaq IPO, the largest biotech listing since 2024, led by former Merck executive Roger Perlmutter Proceeds from the public offering will fund the clinical advancement of Eikon’s oncology pipeline, notably EIK1001, a toll-like receptor 7/8 agonist currently studied with Keytruda in melanoma and lung cancer. Additional programs include PARP1 inhibitors EIK1003 and EIK1004—targeting ovarian, breast, prostate, and pancreatic cancers—and EIK1005, a WRN helicase inhibitor in early-stage development for solid tumours. The company, founded in 2021, continues to build momentum on its immunotherapy and precision oncology strategy, backed by prior multimillion-dollar financing rounds that have supported rapid progression from preclinical research to multiple active phase 1/2 and 2/3 trials across critical cancer indications. (Link)
SpyGlass Pharma (NASD: SGP) launches $150M Nasdaq IPO for advancing long-acting eye drug delivery innovation Funds from the IPO will advance SpyGlass Pharma’s lead candidate, the Bimatoprost Drug Pad-IOL System, a long-acting intraocular lens designed to deliver sustained treatment for glaucoma and ocular hypertension. The device, implanted during cataract surgery, provides years of drug release, potentially eliminating the need for daily eye drops. Proceeds will support two phase 3 clinical trials already underway and a potential commercial rollout upon successful results. Early studies demonstrated significant intraocular pressure reduction, affirming the platform’s promise. SpyGlass joins a wave of biotech companies reinvigorating the IPO market as investors renew interest in ophthalmic and drug-delivery innovations. (Link)
Agomab Therapeutics (NASD: AGMB) raises $200M in Nasdaq IPO to support development of ALK5 inhibitors for fibrostenosing Crohn’s disease and pulmonary fibrosis Proceeds from the IPO will fund Agomab Therapeutics’ next-stage clinical programs, including a global phase 2b trial for ontunisertib, its leading oral ALK5 inhibitor targeting fibro stenosing Crohn’s disease. The company also plans to advance AGMB‑447, another ALK5 inhibitor in phase 1 studies for idiopathic pulmonary fibrosis, toward midstage development. Both candidates were obtained through Agomab’s 2021 acquisition of Origo Biopharma. The IPO proceeds will also bolster operational growth and global research capabilities as Agomab pursues fibrosis-modifying therapies aimed at halting disease progression in patients with chronic intestinal and respiratory conditions. (Link)
Veradermics (NYSE: MANE) raises $256M in NYSE IPO with investment interest from Eli Lilly and Wellington Management to advance oral minoxidil hair regrowth therapy The Connecticut-based biotech’s IPO marks a strong debut, with shares more than doubling in their first trading session. Veradermics focuses on developing VDPHL01, an extended-release oral version of minoxidil, intended to overcome limitations of topical Rogaine. The funds will support phase 3 trials evaluating its efficacy in treating pattern hair loss. Eli Lilly expressed interest in acquiring up to 4.9% of issued shares, while Wellington Management indicated plans to invest up to $30 million. The company seeks to capture a major share of the expanding global hair loss market and lead innovation in convenient, effective hair restoration therapies. (Link)
Kaiser Permanente and Renown Health complete joint venture to jointly own Hometown Health and expand integrated care access in northern Nevada The finalized partnership marks Kaiser Permanente’s entry into northern Nevada through the joint ownership of Hometown Health and collaboration with Renown Health’s established provider network. The venture aims to expand access to affordable, value-based care while integrating insurance coverage and clinical delivery across the region. Kaiser Permanente will open two new medical centers in 2026, adding to its existing Reno location, and plans to introduce its digital health platform and in-house pharmacy network by 2027. The collaboration combines Kaiser Permanente’s national capabilities with Renown’s strong local presence to enhance clinical outcomes and improve patient experience across northern Nevada. (Link)
NuvemRx acquires 340B referral technology company par8o from R1 RCM, via its financial sponsors Parthenon Capital Partners and Rainmaker Strategic Capital to enhance specialty care coordination and expand pharmacy network capabilities The acquisition integrates par8o’s AI-powered referral capture technology with NuvemRx’s pharmacy management and third-party administration services, enabling covered entities to more efficiently manage 340B referrals and specialty prescriptions. The combined platform now supports over 800 covered entities and impacts more than 70 million patients nationwide. By automating up to 85% of the referral and eligibility process, the integration reduces administrative burdens, enhances compliance, and increases savings opportunities for safety-net providers. The move strengthens NuvemRx’s mission to simplify pharmacy operations, expand access to affordable care, and improve coordination across community health and specialty care networks. (Link)
MedRisk to acquire Horizon Casualty Services PPO Network business from Horizon Mutual Holdings, via its financial sponsors CVC Capital Partners and The Carlyle Group to expand managed care capabilities in workers’ compensation and auto casualty markets The acquisition enhances MedRisk’s reach and service offerings within the casualty claims industry by integrating Horizon Casualty Services’ PPO Network business. The move aligns with MedRisk’s strategy to deliver improved patient outcomes, streamlined claims management, and optimized payment solutions. The integration supports faster recovery times, smarter spending, and enhanced client value while reinforcing the company’s commitment to innovation and superior service across workers’ compensation and auto casualty markets. (Link)
Coloplast discloses definitive agreement for Uramedica acquisition in Q1 2025/26 earnings Report Coloplast US signs definitive merger agreement to acquire all outstanding shares of Uromedica, a privately held US medtech company specializing in minimally invasive treatments for stress urinary incontinence, making Uromedica a wholly owned subsidiary. The acquisition is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. The move aligns with Coloplast’s strategy to bolster growth in urology through targeted additions, amid strong organic performance in the division. (Link)
Konovo acquires Rare Patient Voice, via its financial sponsors Bain Capital Credit, Frazier Healthcare Partners, GV Investment Managers and Leavitt Equity Partners to expand access to 200,000+ patients and caregivers The acquisition strengthens Konovo’s healthcare intelligence platform by combining its data-driven capabilities and healthcare provider network with Rare Patient Voice’s extensive, community-driven database of patients and caregivers. This integration enhances the ability of researchers to access hard-to-reach populations and capture real-world patient insights across therapeutic areas. Konovo plans to scale these efforts globally while integrating patient and clinician perspectives into unified, technology-enabled research solutions. The partnership drives faster, more informed decision-making for healthcare organizations advancing innovation in complex diseases. (Link)
RadNet (NASD: RDNT) acquires Northwest Radiology in Indiana, adding six imaging centers to expand Midwest footprint and enhance AI-powered diagnostic services The acquisition marks RadNet’s entry into Indiana, extending its national imaging network into the Midwest through six outpatient centers in the Indianapolis region. Northwest Radiology’s 18 radiologists will continue providing contracted professional services, ensuring continuity and maintaining strong local physician relationships. The integration will leverage RadNet’s advanced imaging technologies and AI-driven workflows to improve early disease detection and overall population health management. With the addition expected to generate approximately $18 million in annual revenue, RadNet aims to expand its proactive diagnostic approach while strengthening patient access to high-quality, cost-effective imaging care across Indiana. (Link)
Nautic Partners completes growth investment in KabaFusion as Novo Holdings exits, supporting expansion of home infusion care services The partnership marks a new phase for KabaFusion, a national leader in home and alternate site infusion therapy. With operations covering 45 states through 33 pharmacies and 21 infusion suites, the company will leverage Nautic Partners’ investment to accelerate its growth and innovation initiatives. KabaFusion’s management team, which remains significant investors, will continue leading the organization to enhance patient access and clinical excellence. The investment underscores Nautic’s strategy of backing mission-driven healthcare providers delivering high-quality, patient-centered care, marking the exit of Novo Holdings following its successful tenure supporting KabaFusion’s nationwide expansion. (Link)
Black Pearl Equities Announces Intention to Commence Tender Offer to Acquire Selectis Health, Inc. Black Pearl Equities, LLC announces intention to commence an all-cash tender offer to acquire all issued and outstanding shares of common stock of Selectis Health, Inc. (OTC: GBCS) at $4.00 per share. The proposed transaction is subject to negotiation and execution of definitive transaction documentation as well as customary closing conditions. Selectis Health operates skilled nursing and transitional care facilities, and this unsolicited proposal follows the company’s recent asset sales and operational streamlining efforts. (Link)
Vanderbilt Health acquires Tennova’s Clarksville Hospital, Tennova ER-Sango, and physician clinics from Community Health Systems to expand regional care network The acquisition expands Vanderbilt Health’s footprint across Middle Tennessee, adding the 270-bed Clarksville hospital, freestanding Sango ER, and multiple physician practices to its growing regional system. Vanderbilt Clarksville Hospital (VCH) will serve as a hub for expanded emergency, surgical, and specialty services, with new paediatric and adult programs planned in collaboration with Monroe Carell Jr. Children’s Hospital. The integration brings nearly 1,100 staff and over 30 physicians into Vanderbilt’s network, reinforcing its commitment to delivering high-quality, community-based care. The move marks Vanderbilt’s fourth regional hospital acquisition, extending its reach beyond Nashville and strengthening access to advanced health services statewide. (Link)
Venture and Other News
Midi Health closes $100M Series D in Goodwater Capital–led round with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens and McKesson Ventures to scale national women’s health platform The virtual women’s health clinic now serves over 230,000 patients across 50 states through a network of 500 providers, treating 25,000 patients weekly. Founded in 2021 to address perimenopause and menopause care, the company is expanding into metabolic health, weight management, and musculoskeletal health. The platform uses AI-powered tools for chart analysis, scheduling, and care protocols while offering insurance-backed services reaching 45 million women. The company reports improved screening adherence rates and up to 13% lower total cost of care, with plans to expand Medicare and Medicaid coverage. (Link)
Chamber raises $60M Series A led by Frist Cressey Ventures with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures to scale cardiology value-based care The funding will accelerate Chamber’s mission to modernize cardiovascular care through value-based models that improve outcomes while lowering costs. The company’s platform integrates AI-driven insights to help cardiologists identify high-risk patients, close care gaps, and streamline workflows within existing systems. Partnering with both payers and practices, Chamber supports data-informed, proactive management of chronic heart disease. With more than 500 cardiologists across seven states already on its network, the company plans to expand its national footprint and strengthen partnerships with health plans. The investment underscores growing momentum behind value-based innovations addressing cardiovascular care delivery and patient experience. (Link)
Alaffia Health raises $55M Series B led by Transformation Capital with FirstMark Capital, Tau Ventures, and Twine Ventures to expand AI-driven health plan operations The latest funding round accelerates Alaffia Health’s mission to reduce healthcare’s $570 billion in administrative waste through advanced, clinically informed AI for health plan claims management. The company’s platform combines physician oversight with agentic AI to enhance accuracy, speed reviews, and achieve measurable cost savings for national and regional payers. Delivering over 20% savings on high-cost claims and fivefold ROI, Alaffia plans to use the new capital for R&D, product innovation, and scaling adoption across the healthcare ecosystem. The investment supports ongoing efforts to create transparent, compliant, and efficient claims infrastructure that strengthens affordability and systemwide operational performance. (Link)
Third Arc Bio raises $52M Series A extension led by Andreessen Horowitz with Omega Funds, Goldman Sachs Alternatives, BVF Partners, T. Rowe Price, Galapagos NV, AbbVie Ventures and Alderline Group to advance oncology and immunology pipeline The funding strengthens Third Arc Bio’s efforts to expand its multifunctional antibody programs in oncology and immunology. The capital will accelerate clinical development of the company’s lead asset, ARC101—a bispecific T cell engager targeting CLDN6 in advanced solid tumours—while advancing next-generation inflammation and immune modulation candidates toward human trials. Leveraging its ARCTag (Tethered Agonist) platform, Third Arc Bio aims to localize immune activity precisely at disease sites, enhancing efficacy and reducing systemic toxicity. Supported by a seasoned scientific team, the company continues to validate its platform approach to develop targeted biologics addressing major unmet medical needs. (Link)
Market Rumours
Seed Health reportedly retains Centerview Partners to explore potential sale amid strong financial performance Seed Health has reportedly hired Centerview Partners to advise on a potential sale as it attracts strong interest from strategic and private equity buyers. Generating about $200 million in revenue and over $50 million in EBITDA, the company aims to leverage rising global demand for premium probiotics and wellness products.
HHAeXchange reportedly explores sale with Centerview Partners advising; backed by Cressey & Company and Hg Capital The company, generating about $100 million in recurring revenue, develops software that streamlines compliance and operations for Medicaid homecare providers. Having expanded through acquisitions of Sandata Technologies, Generations Homecare Systems, and Cashe Software, it reflects growing investor interest in post‑acute healthcare tech consolidation during ongoing strategic review discussions.
